- Home
- SND vs GALT Comparison
SND vs GALT Comparison
Compare SND & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SND | GALT |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | 318 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 199.2M |
| IPO Year | 2016 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SND | GALT |
|---|---|---|
| Price | $4.58 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 256.5K | ★ 293.3K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $172.50 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $1.76 | $1.22 |
| 52 Week High | $5.84 | $7.13 |
Technical Indicators
Market Signals| Indicator | SND | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 44.38 |
| Support Level | $3.56 | $2.18 |
| Resistance Level | $5.69 | $2.60 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 25.27 | 46.24 |
Price Performance
Historical ComparisonAbout SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.